Within-host spatiotemporal dynamics of systemic Salmonella infection during and after antimicrobial treatment by Rossi, Omar et al.
Within-host spatiotemporal dynamics of systemic Salmonella infection
during and after antimicrobial treatment
O. Rossi*, R. Dybowski, D. J. Maskell, A. J. Grant, O. Restif† and P. Mastroeni†
University of Cambridge, Department of Veterinary Medicine, Cambridge, UK
*Corresponding author. Department of Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge CB30ES, UK.
Tel: !441223765811; Fax: !441223337610, E-mail: or265@cam.ac.uk
†These authors contributed equally.
Received 15 May 2017; returned 22 June 2017; revised 28 June 2017; accepted 20 July 2017
Objectives: We determined the interactions between efficacy of antibiotic treatment, pathogen growth rates
and between-organ spread during systemic Salmonella infections.
Methods: We infected mice with isogenic molecularly tagged subpopulations of either a fast-growing WT or a
slow-growing DaroC Salmonella strain. We monitored viable bacterial numbers and fluctuations in the propor-
tions of each bacterial subpopulation in spleen, liver, blood and mesenteric lymph nodes (MLNs) before, during
and after the cessation of treatment with ampicillin and ciprofloxacin.
Results: Both antimicrobials induced a reduction in viable bacterial numbers in the spleen, liver and blood. This
reduction was biphasic in infections with fast-growing bacteria, with a rapid initial reduction followed by a phase
of lower effect. Conversely, a slow and gradual reduction of the bacterial load was seen in infections with the
slow-growing strain, indicating a positive correlation between bacterial net growth rates and the efficacy of
ampicillin and ciprofloxacin. The viable numbers of either bacterial strain remained constant in MLNs throughout
the treatment with a relapse of the infection with WT bacteria occurring after cessation of the treatment. The
frequency of each tagged bacterial subpopulation was similar in the spleen and liver, but different from that of
the MLNs before, during and after treatment.
Conclusions: In Salmonella infections, bacterial growth rates correlate with treatment efficacy. MLNs are a site
with a bacterial population structure different to those of the spleen and liver and where the total viable bacterial
load remains largely unaffected by antimicrobials, but can resume growth after cessation of treatment.
Introduction
Bacterial diseases pose a grave threat for humankind, causing ap-
proximately six million deaths per year.1 Antibiotics are key weap-
ons against bacterial infections. However, antimicrobial treatment
does not always result in the complete resolution of acute bacter-
ial infections even when the pathogen retains susceptibility to the
drugs used.2,3 Post-treatment persistence of antibiotic-susceptible
bacteria is increasingly being recognized as a situation of great
medical importance and can lead to disease reservoirs, continued
transmission and in some cases within-host relapses, especially in
immune-deficient individuals.2,4–9 The reasons why many anti-
microbials are far less effective in vivo than in in vitro are difficult to
explain. It is likely that key parameters of in vivo pathogen behav-
iour, such as location, division and spread within and between dif-
ferent organs, would have an impact on the therapeutic potential
offered by antimicrobials.10–18
The aim of this study was to determine whether the in vivo net
growth rate of Salmonella affects the efficacy of ampicillin and
ciprofloxacin, representatives of two classes of antimicrobials
(b-lactams and fluoroquinolones) commonly used for the treat-
ment of systemic salmonelloses in mammalian species.13 We
used a tractable murine in vivo model that captures many essen-
tial traits of systemic Salmonella infections of humans and other
animals. This model captures, with the highest level of concord-
ance, the pathogenesis of invasive salmonelloses in humans and
other animals and has indicated the path for antimicrobial treat-
ment.8,9,19–23 Murine infections with fast-growing bacteria mimic
closely the pathogenesis of non-typhoidal salmonelloses while in-
fections with slow-growing bacteria closely resemble typhoid and
paratyphoid fever.
We compared ampicillin and ciprofloxacin because they exhibit
differences in their mechanisms of action that can be predicted to
result in different levels of dependence on bacterial division rates
VC The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
1 of 8
J Antimicrob Chemother
doi:10.1093/jac/dkx294
Downloaded from https://academic.oup.com/jac/article-abstract/doi/10.1093/jac/dkx294/4093161/Within-host-spatiotemporal-dynamics-of-systemic
by University of Cambridge user
on 05 September 2017
for optimal efficacy. Ampicillin treatment inhibits cell wall biosyn-
thesis and therefore its bactericidal action depends on bacterial
division. Ciprofloxacin inhibits DNA gyrase and DNA topoisomerase
IV; these enzymes are involved in many cellular processes that in-
volve duplex DNA (i.e. replication, recombination and transcription)
and therefore the action of ciprofloxacin can be predicted to be
less dependent on the division rate of the bacterial strain.24
Understanding the efficacy of antimicrobials in different organs
is necessary to improve their in vivo use and to maximize treat-
ment efficacy. We therefore asked whether the antimicrobials are
equally effective in different tissues [i.e. spleen, liver, mesenteric
lymph nodes (MLNs) and blood] and how bacterial spread of the
infection between body sites is affected by the antimicrobial treat-
ment and its cessation.
We infected mice intravenously with mixes of isogenic tagged
strains (ITS) that contain specific nucleotide sequences that do not
alter pathogen fitness, but enable the quantification of each tagged
subpopulation in vivo.12,25 Using this approach we have already
determined the dynamics of growth and spread of Salmonella
within and between organs,12 and we have been able to under-
stand how immune pressure and vaccines affect the infection pro-
cess at the level of individual bacterial subpopulations.26
In this study, we compared the effect of antimicrobials on fast-
growing wild-type ITS (WITS) and on slow-growing DaroC mutant
ITS (MITS).27 We determined the total bacterial viable counts in
spleens, livers, MLNs and blood before, during and after cessation
of antimicrobial treatment. We also determined the presence and
proportional frequency of each ITS within each organ as a proxy of
the bacterial spread between organs or confinement of ITS to an
individual body site.
Materials and methods
Bacterial strains
We generated eight fast-growing WITS12 and eight slow-growing DaroC
MITS27,28 using the virulent Salmonella enterica serovar Typhimurium strain
SL134427 as the parent strain (details of the aroC defined mutation, and of
MITS and WITS generation are listed in the Supplementary methods,
Appendix 1 and Table S1, available as Supplementary data at JAC Online).
Standard methods and reagents were used for molecular cloning29 and for
integration of linear DNA fragments into the chromosome of Salmonella re-
cipient cells using a modification of the method of Datsenko and
Wanner.12,30 Each of the eight WITS or MITS contains a different 40 bp DNA
signature tag in the same non-coding region of the chromosome; this en-
ables the discrimination and quantification of each WITS- or MITS-tagged
strain (subpopulation) in a mixed sample.12 Similar MICs of ampicillin and
ciprofloxacin and similar net growth rates in vitro and in vivowere observed
within each set of eight WITS and within each set of eight MITS (data not
shown).
Infections and antimicrobial treatments
Female, age-matched C57BL/6 mice were purchased from Envigo UK, and
used when over 8 weeks of age (mean weight 20+3 g). The mice were
housed in specific pathogen-free containment facilities and were allowed
water and food ad libitum. WITS and MITS were grown individually from
glycerol stocks for 24 h at 37 C on LB agar supplemented with the appropri-
ate antimicrobials (50 mg/L kanamycin for WITS, 50 mg/L kanamycin and
20 mg/L tetracycline for MITS), before being grown in LB broth statically at
37 C for 16 h. Cultures of individual WITS or MITS were pooled (as eight
WITS or eight MITS), diluted in sterile PBS (Sigma–Aldrich) and injected
iv into a lateral tail vein. Ampicillin sodium salt and ciprofloxacin hydrochlor-
ide powders (Sigma–Aldrich) were dissolved in endotoxin-free water
(Sigma–Aldrich) and administered by ip injection (in 0.2 mL volume) at 12 h
intervals for 4 days. The maximum recommended dosage for veterinary
treatment of small rodents was used (150 mg/kg/dose for ampicillin treat-
ment and 20 mg/kg/dose in the case of ciprofloxacin treatment).31,32
We chose an inoculum dose of 103 cfu for infections with WITS. This
allowed measurement of fluctuations in the heterogeneity of WITS subpo-
pulations without stochastic loss of any subpopulation in livers and spleens
and only moderate stochastic loss of subpopulations in MLNs at 72 h after
iv infection.12 The MITS infection dose was set at 106 cfu in order to achieve
on day 3 (before the start of antimicrobial treatment) viable bacterial
counts in the tissues at levels similar to those of the WITS.33
Groups of mice (Table S2) were killed before the start of the antimicro-
bial treatments (3 days post-infection) and every 24 h during the 4 days of
treatment, and at two further timepoints after cessation of drugs (1 and
2 days, or 7 and 13 days after cessation of antimicrobials for WITS and MITS
infections, respectively).
Ethics
All animal experiments were performed in accordance with good animal
practice as defined by the relevant international (Directive of the European
Parliament and of the Council on the Protection of Animals Used for
Scientific Purposes, Brussels 543/5) and local (University of Cambridge) ani-
mal welfare guidelines. This research has been regulated under the
Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012 fol-
lowing ethical review by the University of Cambridge Animal Welfare and
Ethical Review Body (AWERB).
Enumeration and recovery of viable Salmonella
in organs
Blood was collected from a tail artery (approximately 0.4 mL of blood per
animal) in heparin-coated tubes. Mice were killed by cervical dislocation
and spleens, livers and MLNs were removed and individually homogenized
in molecular-grade sterile water (5 mL for livers and spleens, 2 mL for
MLNs) using a Stomacher 80 (Seward). Homogenates were plated onto LB
agar. If required, serial 10-fold dilutions in PBS were used to enumerate vi-
able bacteria. The cfu for the blood were calculated assuming a total circu-
lating volume of 2 mL.
All the colonies obtained from each organ/blood after overnight incuba-
tion at 37 C were harvested and resuspended in 2 mL of sterile PBS in the
case of livers and spleens, or in 1 mL of sterile PBS for blood and MLNs sam-
ples. Recovered bacterial suspensions were thoroughly mixed, and aliquots
were stored at#80 C prior to genomic DNA extraction.
Determination of ITS proportions in bacterial samples
by amplicon sequencing
We determined ITS proportions within samples using a sequencing-based
approach adapting the 16S library preparation guide from Illumina.34 Briefly,
genomic DNA was purified from aliquots of the bacteria recovered from the
agar plates (5%109 cfu) using a DNeasy Blood and Tissue kit (Qiagen).
25 ng DNA from each sample was used as template for a first PCR to amplify
113 bp regions containing the unique nucleotide signatures from each sam-
ple (composed of a mix of the various DNA tags differentiating the various
ITS). DNA was purified using AMPure beads (Beckman Coulter) and indexed
(using a Nextera XT Index kit; Illumina) by a second PCR to enable the
sequencing (and the multiplexing) by Illumina technology. For each sample,
25 ng of DNA was pooled, and the library was assayed and quality checked
by NEBNext Library Quant Kit for Illumina (New England Biolabs). Finally,
20 pM of library (denatured with NaOH) was spiked with 5% PhiX control
(Illumina) and sequenced using a MiSeq (Illumina). Automated image
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analysis, base-calling, data quality assessment and de-multiplexing were
performed by the MiSeq instrument. The number of reads containing the
specific tags was determined using an R-based script and this information
was subsequently used to establish the presence, absence and relative
abundance of each tagged strain within each sample.
Statistical analysis and data processing
Variations in bacterial loads per organ were analysed using a linear model,
with log-transformed cfu as a response variable, and strain, antimicrobial,
organ, day and day2 (to account for non-linear dynamics) as explanatory
variables, using the lm function in R version 3.3.35 We used analysis of vari-
ance (ANOVA) and backward elimination of non-significant (P.0.05) terms
to produce a minimal model. The analysis was repeated separately for each
strain, for MLNs only, and without the MLNs (because of their clearly distinct
dynamics). The ANOVA tables are reported in Appendix 2 (Tables S3–S12).
In order to detect systemic movement of bacteria between organs, we
then compared the distributions of the eight tags (WITS or MITS) between
pairs of organs within mice at each timepoint. This was performed by boot-
strapped null distributions (under the assumption that the ITS populations
in the pair of organs considered had been sampled from the same pool)
using the geometric mean of each bootstrap sample as the statistic. Bias
correction was applied as proposed by Davison and Hinkley,36 and adjusting
the estimated P values using the Holm–Bonferroni method.37 A complete
description of the algorithm and the adjusted P values obtained are re-
ported in Appendix 3 (Tables S13 and S14). All hypothesis tests were per-
formed at the 5% significance level (P0.05).
WITS or MITS analysis by amplicon sequencing was validated, and
proportionality was determined, as well as the level of background noise
(i.e. reads assigned to WITS or MITS in the absence of that DNA).
Consequently, a ‘technical’ cut-off equal to 1240 reads (representing the
background noise) was applied, and thus any value less than 1240 was re-
set to zero. A ‘biological’ cut-off was also set to 1 bacterium: if the product
of a total bacterial load with the proportion of a WITS or MITS was,1, then
the frequency of that WITS or MITS was reset to zero.
Results
Efficacy of ampicillin and ciprofloxacin on bacteria with
fast and slow in vivo net growth rates
We injected different groups of mice with either the fast-growing
WITS or the slow-growing MITS. The mice received either ampicillin
or ciprofloxacin from day 3 of the infection for 4 days.
Figure 1 (top panels) shows a biphasic effect of both anti-
microbials in the spleen and liver. The numbers of viable WITS
decreased by approximately 99% in the first 3 days of treatment
[days 3–6 post-infection (p.i.)] with no further significant reduc-
tions being observed after two more doses of either antimicrobial
(i.e. between days 6 and 7 p.i.). This was confirmed statistically
by a significant and positive quadratic effect of time in the
ANOVA (Tables S4 and S7). Ampicillin showed a more marked ef-
fect on the overall reduction in viable bacterial numbers in the
liver as compared with the spleen, while the effect of treatment
with ciprofloxacin was similar in both organs (Table S7). The hep-
atic viable bacterial loads were similar in the livers at the end of
treatment with either antimicrobial (P"0.17 by Mann–Whitney
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Figure 1. Bacterial loads in different organs at various timepoints post-infection. Different groups of C57BL/6 mice were infected iv with equal mixes
of eight WITS to a total dose of 1000 cfu, or eight MITS for a total dose of 5%105 cfu. Each symbol represents total cfu count from an organ of a
single mouse. Solid lines join the median of cfu values for each organ. Light yellow background indicates the phase of antimicrobial treatment (ip for
4 days every 12 h). This figure appears in colour in the online version of JAC and in black and white in the printed version of JAC.
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test at day 7 p.i.), whereas the efficacy of ampicillin was less than
that of ciprofloxacin treatment in the spleen (P,1%10#4 by
Mann–Whitney test at day 7 p.i.; Table S7). Bacteraemia was
reduced by both antimicrobial treatments, with only a minority
(6/20) of mice having detectable numbers of WITS (,10 cfu/mL)
in the blood by day 7 p.i.. Treatment with ampicillin or ciprofloxa-
cin did not reduce the viable numbers of WITS bacteria in MLNs
(no effect of time, P"0.4, Table S6). However, cessation of the
antimicrobial treatment resulted in the relapse of bacterial
growth at similar rates in all the organs (3-fold increase per day),
including MLNs, and the resurgence of bacteraemia (Table S10).
We then proceeded to study the effect of antimicrobial treat-
ment on an infection with slow-growing MITS (Figure 1, bottom
panels). In the infection with the attenuated strain both ampicillin
and ciprofloxacin induced a lower and steady reduction in viable
bacterial numbers compared with what was observed in the infec-
tion with WT bacteria in livers and spleens (approximately 90% in
infection with MITS as compared with approximately 99% in the
infection with WITS), with ciprofloxacin again having a stronger ef-
fect than ampicillin in the spleen (P"0.01, Table S8). Bacteraemia
was gradually reduced to below detectable limits in the majority
(7/12) of animals by the end of the treatment. The viable numbers
of MITS in MLNs remained unaffected by the treatment with either
antimicrobial (removing time from the model had no significant ef-
fect on the ANOVA, Appendix 2). After the cessation of treatment,
there was no evidence of relapse. MITS loads continued to slowly
decrease in livers and spleens, bacteraemia remained undetect-
able or at a low level, while viable bacterial loads persisted in the
MLNs at constant levels (Table S12).
MLNs have different WITS and MITS population
structures from those of the spleens, livers and blood
We showed that antimicrobial treatment fails to reduce viable
bacterial numbers in MLNs in contrast with the reduction in bacter-
ial loads seen in the spleen, liver and blood. However, in infections
with WITS a rapid resurgence of bacterial growth was seen in all
organs including MLNs. This could be due to the growth of WITS
from within MLNs following the interruption of antimicrobial treat-
ment, or could be due to dissemination into the MLNs of bacterial
populations growing in the spleen and liver. To test which of these
scenarios was the most plausible, we compared the relative pro-
portions of each of the WITS (population structure) in the spleen,
liver and MLNs of each mouse at each timepoint, before, during
and after antimicrobial treatment (Figure 2). We found that the
WITS population structure was similar in the spleen and liver of
each mouse (Figure 2a) (visually indicated by the dots, represent-
ing WITS frequencies, falling close to or on the diagonal line in
the graphs). This was confirmed by pairwise comparisons of
WITS composition between organs by bootstrap analysis
(Supplementary Material Appendix 3). Within each mouse, the
WITS population structure in MLNs was different from that of the
spleen (Figure 2b) and liver (Figure 2c), throughout the experiment
(all bootstrapped P,0.01, Appendix 3). These differences ex-
tended to the post-treatment phase of relapse, indicating that the
increase in WITS cfu numbers in the MLNs could not have been
driven by an influx of bacteria from the spleen or liver. We also
found that on day 3 p.i. (before the start of treatment), 4 p.i. (after
1 day of treatment), and 8 and 9 p.i. (the relapse phase) all the
WITS that were present in the blood were also present in the
spleen and liver, but not in the MLNs, suggesting lack of coloniza-
tion of MLNs from the blood (Appendix 4, Figure S1).
Likewise, the population structure of the slow-growing MITS
was indistinguishable between spleens and livers of each mouse
(Figure 3a and Appendix 3), but different from that of the MLNs
throughout the experiment (Figure 3b and c and Appendix 3). This
indicates that the residual MITS population found in the MLNs after
cessation of treatment does not significantly mix with that of the
spleen and liver.
Discussion
This study provides a direct in vivo comparison of the effects of
treatment with two antimicrobials of clinical relevance on bacteria
with fast or slow division rates. We showed that treatment with
ampicillin or ciprofloxacin had a more marked in vivo effect on in-
fections with fast-growing than slow-growing salmonellae.
We showed that the activity of ampicillin and ciprofloxacin is bi-
phasic in infections with fast-growing bacteria but not with slow-
growing ones. In fact, we found that the reduction in the numbers
of bacteria that can be cultured from the spleen and liver hom-
ogenates occurs rapidly in the first 3 days of treatment with fast-
growing WITS. No further reduction was observed on the fourth
day following the last two doses of antimicrobials, leading to a
situation where the bacteria are refractory to further antimicrobial
treatment and persist in the tissues. The reasons for this biphasic
effect of antimicrobial treatment are unclear. Salmonella is found
in different cell types and also within multicellular pathological le-
sions that form at the sites of infections as a consequence of the
onset and escalation of the innate immune response.38–43 These
locations could represent privileged sites that are poorly accessible
to antimicrobials where a fraction of the WITS bacterial load that
escapes the initial rapid killing could persist. However, we did not
observe the same biphasic effect of the treatment in mice infected
with slow-growing MITS, where a constant decline in the number
of bacteria that could be cultured was observed throughout the
4 days of treatment. This suggests that scenarios other than loca-
tion are also likely to contribute to the dynamics of bacterial death
and survival during antimicrobial treatment. For example, it is pos-
sible, and likely, that the selection of bacterial populations with low
division rates and/or that are non-replicating are causal factors in
post-treatment persistence.44–49 It is also possible that the hetero-
geneity in bacterial division rates or the percentage of non-
replicating bacteria is higher in the overall initial (pre-antimicrobial
treatment) WITS population as compared with the MITS, leading
to the presence of fast-replicating WITS subpopulations easily
killed by the antimicrobials and slower ones that may persist.
Our data show that neither antimicrobial treatment caused
statistically significant changes in the viable bacterial numbers in
MLNs. Although these have been reported as a site of Salmonella
persistence,47,48,50,51 here we show that, surprisingly, MLNs are a
site where no reductions in bacterial loads can be achieved by ad-
ministration of ampicillin or ciprofloxacin. We currently do not
have a simple mechanistic explanation for this phenomenon. It is
possible that there is a fine balance between bacterial growth in
between treatments in the MLNs and killing of bacteria by the anti-
biotics, leading to overall constant numbers of viable bacteria at
the times of observation. It also possible that the majority of the
Rossi et al.
4 of 8
Downloaded from https://academic.oup.com/jac/article-abstract/doi/10.1093/jac/dkx294/4093161/Within-host-spatiotemporal-dynamics-of-systemic
by University of Cambridge user
on 05 September 2017
bacteria in the MLNs enter a non-replicative state, with only a small
proportion of bacteria growing rapidly in between treatments and
being killed by the antibiotics. These growing populations would be
responsible for the observed relapse of the infection after cessation
of treatment. However, this hypothesis is in disagreement with:
(i) the fact that the reported high initial percentage of non-
replicating bacteria within MLNs is known to decrease as the
infection progresses, with only approximately 10% of bacteria in
the MLNs not having replicated (and therefore potentially refrac-
tory to antimicrobials) by 24 h after inoculation;45 and (ii) the ob-
servation that the heterogeneity of tagged strains within the MLNs
does not increase during the treatment phase.
We found that the relapse of bacterial growth in the MLNs was
not driven by migration of Salmonella from other body sites, as the
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Figure 2. Pairwise distribution of the eight WITS in different organs for each mouse: (a) spleen versus liver; (b) spleen versus MLNs; and (c) liver versus
MLNs. Each dot shows the frequency of a single WITS coded by colour. Each panel shows data from all the mice treated with a given antimicrobial
and euthanized on a given day. Light yellow background indicates the time of antimicrobial treatment. This figure appears in colour in the online ver-
sion of JAC and in black and white in the printed version of JAC.
Impact of antimicrobials on Salmonella infection dynamics JAC
5 of 8
Downloaded from https://academic.oup.com/jac/article-abstract/doi/10.1093/jac/dkx294/4093161/Within-host-spatiotemporal-dynamics-of-systemic
by University of Cambridge user
on 05 September 2017
compositions of WITS and MITS in the MLNs remained distinct
from those of bacteria in livers and spleens. Overall this indicates
that MLNs are a compartmentalized privileged site for Salmonella
where the bacterial load becomes completely refractory to reduc-
tions via antimicrobial treatment and can resume growth or persist
after cessation of therapy.
This study indicates complex in vivo scenarios. The mechanisms
that underpin bacterial location, division and interaction with host
cells in vivo under antimicrobial pressure within the complexity of a
whole mammalian organism remain unclear. This lack of know-
ledge currently hampers our ability to design in vivo approaches to
target those bacteria that are poorly susceptible to treatment.
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Figure 3. Pairwise distribution of the eight MITS in different organs for each mouse: (a) spleen versus liver; (b) spleen versus MLNs; and (c) liver versus
MLNs. Each dot shows the frequency of a single MITS coded by colour. Each panel shows data from all the mice treated with a given antimicrobial
and euthanized on a given day. Light yellow background indicates the time of antimicrobial treatment. This figure appears in colour in the online ver-
sion of JAC and in black and white in the printed version of JAC.
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